Is the Options Market Predicting a Spike in Sarepta Therapeutics (SRPT) Stock?Zacks Investment Research • 08/22/19
Why Madison Square Garden, Hain Celestial Group, and Sarepta Therapeutics Slumped TodayThe Motley Fool • 08/20/19
Why The FDA Left Sarepta To 'Twist In The Wind' Over Its Newest DrugInvestors Business Daily • 08/20/19
Sarepta Dives After FDA Rejects Its Newest Muscular Dystrophy DrugInvestors Business Daily • 08/19/19
Sarepta Therapeutics Receives Complete Response Letter from the US Food and Drug Administration for Golodirsen New Drug ApplicationGlobeNewsWire • 08/19/19
Sarepta Therapeutics Inc (SRPT) President & CEO Douglas S Ingram Bought $2 million of SharesGuruFocus • 08/12/19
This Biotech Crashed Before Trading Halted — Plus 2 Stocks That DivergedInvestors Business Daily • 08/08/19
Sarepta Therapeutics, Inc. (SRPT) CEO Douglas Ingram on Q2 2019 Results - Earnings Call TranscriptSeeking Alpha • 08/08/19
Has Sarepta Therapeutics (SRPT) Outpaced Other Medical Stocks This Year?Zacks Investment Research • 08/06/19